The Access Blind Spot in China-Licensed Assets

The China story is being told as an innovation and financing story. China did not invent antibody–drug conjugates, T-cell engagers, or degraders — but it has commoditised them, applied them across dozens of targets in parallel, and moved them into the clinic faster than anyone else. Western investors can now license a Chinese asset with early human data rather than preclinical biology, and the old scepticism about Chinese data has largely faded. The capital is following: licensing deals, direct investment, and a generation of US-trained founders building in Shenzhen rather than Boston.

That shift is real, and it is bigger than the market is pricing in. But the diligence around it is asking the wrong final question.

Buyers are pricing the science — is the data real? — and the deal — what is the multiple? Almost no one is pricing the access risk that travels with the asset: a molecule optimised for Chinese — or even US — approval is not automatically a reimbursable, well-priced product in Europe. The value of these assets at partnering or exit depends on payer credibility in markets built on structurally different evidence and pricing logic than the one the asset was developed in. That risk is currently unpriced, and it is where the value quietly leaks.

License a Chinese-originated asset into Western markets — Europe, the US — and you inherit three gaps its originators never had to close.

The evidence gap

EU Joint Clinical Assessment, live since 2025 for oncology and advanced therapies, asks a comparative-effectiveness question — relative to the European standard of care, under a defined PICO scope — that a registrational package built for a different system frequently cannot answer. Single-arm or non-comparative data, and questions about the generalisability of a China-based trial population to European practice, are not regulatory footnotes. They are the difference between a reimbursed launch and a stranded one. The decisive question is which gaps are still closeable before readout and which are now structural.

The pricing gap

Europe's reference-pricing linkages mean a price set early, or set low, in one market propagates across the basket. An asset whose Western launch is sequenced without that contagion in mind can erode its own net value across a dozen markets before anyone notices — compounded now by MFN and IRA exposure on the US side. Price is not a number you set at launch. It is a corridor you have to protect from the first market onward.

The launch gap

The originator built for speed to clinic, not for a Western access narrative. The licensee inherits an asset with strong data and no launch sequence, no payer-engagement plan, and no value story tuned to European HTA. The science arrives; the commercialisation strategy does not.

The fix is earlier diligence, not more of it

None of this argues against the deals. The assets are good and the thesis is sound. It argues that diligence which stops at the molecule and the term sheet is incomplete — and that the gap is most acute precisely where the deal flow is heaviest.

The fix is not complex, but it has to happen before the deal, not after. A fast, structured read on three questions: where the evidence package sits against EU comparative-effectiveness expectations and which gaps are still fixable; the defensible pricing corridor and the reference-pricing linkages that constrain it; and the launch sequence the asset needs to protect its value in the West. That is a one-to-two-week exercise, and it changes both the price you should pay and the plan you inherit.

One conversation, not three

Capital allocation, evidence expectations, and commercialisation strategy are converging into one conversation rather than three separate workstreams. Nowhere is that convergence sharper than in the China-to-West asset flow — where the people writing the cheques and the people who will eventually have to win reimbursement are, for now, still working from different maps.